Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1420 ARTÍCULOS , VIENDO DEL 1171 AL 1185

Serious doubts about amyloid-β (Aβ) biomarkers and anti-Aβ immunotherapy

Høilund-Carlsen PF, Alavi A, Costa T, Neve RL, Revheim ME, Barrio JR.

J Alzheimers Dis. 2026 Apr;110(3):1079-1084. doi: 10.1177/13872877261417548. Epub 2026 Mar 20.

Blood-based biomarkers for Alzheimer's disease: Advances in early detection and monitoring of age-related neurodegeneration

Fu W, Ho PC.

Ageing Res Rev. 2026 May;117:103058. doi: 10.1016/j.arr.2026.103058. Epub 2026 Feb 8.

Biomarkers for Alzheimer's disease and mild cognitive impairment: Recent advances in task-based EEG

Tripanpitak K, Wolf A, Kapitonova M, Umeda S, Ball T, Otake-Matsuura M.

J Alzheimers Dis. 2026 Mar;110(1):58-73. doi: 10.1177/13872877251413700. Epub 2026 Feb 4.

Alzheimer's disease: Time to reassess research and clinical priorities

Wiatrak B, Szeląg A.

Adv Clin Exp Med. 2026 Mar;35(3):397-401. doi: 10.17219/acem/217199.

Plasma Phosphorylated Tau 217 and Amyloid Burden in Older Adults Without Cognitive Impairment: A Meta-Analysis

Malek-Ahmadi M, Sharma S, Stipho F, Denkinger M, Singh A, Brum WS, Ashton NJ.

JAMA Neurol. 2026 Jan 1;83(1):13-19. doi: 10.1001/jamaneurol.2025.4721.

Alzheimer's disease

Serrano-Pozo A, Escott-Price V, Grinberg LT, Pascoal T, Suárez-Calvet M, Dubois B, Sperling RA.

Lancet. 2026 May 30;407(10544):2241-2262. doi: 10.1016/S0140-6736(26)00198-4.

Biofluid biomarkers in Alzheimer's disease and other neurodegenerative dementias

Zetterberg H, Bendlin BB.

Nature. 2026 Feb;650(8100):49-59. doi: 10.1038/s41586-025-10018-w. Epub 2026 Feb 4.

Clinical Practice Recommendations of the Swiss Society for Neuroradiology: Neuroimaging Standards for Enrollment and Disease Monitoring in Anti-Amyloid Immunotherapies

Wiest R, Radojewski P, Lieb JM, Psychogios M, Benzinger TLS, Franceschi AM, Wanke I, Draganski B, Kurz FT, Lövblad KO.

Neurodegener Dis. 2026;26(2):77-88. doi: 10.1159/000549521. Epub 2025 Nov 12.

Relationship between cerebrospinal fluid catecholamines levels and biomarkers of Alzheimer's disease, inflammation and neuronal injury

Portela Moreira I, Serrão P, Sequeira L, Sá MJ, Vieira-Coelho MA, Guimarães J.

Neurol Res. 2026 Jun;48(6):732-742. doi: 10.1080/01616412.2025.2542944. Epub 2025 Aug 3.

Validity and reliability of the Turkish version of the Australian National University-Alzheimer's Disease Risk Index (ANU-ADRI)

Mutlay F, Cam Mahser A, Soylemez BA, Ates Bulut E, Petek K, Ontan MS, Kaya D, Guney S, Isik AT.

Appl Neuropsychol Adult. 2026 Mar-Apr;33(2):461-466. doi: 10.1080/23279095.2024.2369657. Epub 2024 Jun 25.

The Basis of Anti-Aβ Antibody Therapy: The Toxicity of Aβ Aggregates and the Mechanism of Action of Anti-Aβ Antibodies

Ono K, Noguchi-Shinohara M, Watanabe-Nakayama T.

Intern Med. 2026 Jan 1;65(1):41-45. doi: 10.2169/internalmedicine.4569-24. Epub 2024 Oct 4.

Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody

Noguchi-Shinohara M, Ono K.

Intern Med. 2026 Jan 1;65(1):67-70. doi: 10.2169/internalmedicine.4604-24. Epub 2024 Oct 11.

Acute exercise alters brain glucose metabolism in aging and Alzheimer's disease

Green ZD, John CS, Kueck PJ, Blankenship AE, Kemna RE, Johnson CN, Yoksh LE, Best SR, Donald JS, Mahnken JD, Burns JM, Vidoni ED, Morris JK.

J Physiol. 2026 Mar;604(6):2473-2490. doi: 10.1113/JP286923. Epub 2024 Sep 11.

The DDQ-30, a new naming-from-definition test: Normative data for the adult French-Quebec population and validation study in mild cognitive impairment and Alzheimer's disease

Macoir J, Febbrari R, Fiset N, Mulet-Perreault H, Laforce R, Hudon C.

Appl Neuropsychol Adult. 2026 Jan-Feb;33(1):73-83. doi: 10.1080/23279095.2024.2333327. Epub 2024 Mar 28.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias